Want to see FR:VIRP full AI Analyst Report?
Top Page
Virbac SA
(VIRP)
Select Model
Select Model
Rating:69Neutral
Price Target:
€332.00
▲(2.79% Upside)
Action:Reiterated
Date:08/04/26
The score is driven primarily by solid financial fundamentals (steady growth, durable margins, and a conservatively positioned balance sheet), partially offset by only moderate and weakening cash conversion. Technical signals are neutral-to-mildly positive, and valuation appears reasonable but not compelling given the low dividend yield.
Positive Factors
Accelerating revenue growth
Steady revenue expansion, with clear acceleration in 2024–2025, indicates strengthening demand across Virbac’s animal-health portfolio. Sustained top-line growth can support ongoing investment in products and commercial reach, reinforcing the company’s earnings base over the next several quarters.
Negative Factors
Moderate cash conversion
Positive operating and free cash flow are supportive, but the decline in free-cash-flow conversion shows that reported earnings are not translating into cash as efficiently as before. Working-capital or investment needs may therefore create volatility and limit internally funded flexibility.
Read all positive and negative factors
Positive Factors
Negative Factors
Accelerating revenue growth
Steady revenue expansion, with clear acceleration in 2024–2025, indicates strengthening demand across Virbac’s animal-health portfolio. Sustained top-line growth can support ongoing investment in products and commercial reach, reinforcing the company’s earnings base over the next several quarters.
Read all positive factors
Virbac SA (VIRP) vs. iShares MSCI France ETF (EWQ)
Market Cap
€2.91B
Dividend Yield0.42%
Average Volume (3M)6.46K
Price to Earnings (P/E)18.7
Beta (1Y)0.58
Revenue Growth4.30%
EPS Growth17.11%
CountryFR
Employees6,442
SectorGeneral
Sector StrengthN/A
IndustryDrug Manufacturers - General
Share Statistics
EPS (TTM)18.57
Shares Outstanding8,390,660
10 Day Avg. Volume5,028
30 Day Avg. Volume6,456
Financial Highlights & Ratios
PEG Ratio5.39
Price to Book (P/B)2.67
Price to Sales (P/S)2.05
P/FCF Ratio29.01
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)20.85
Revenue Forecast (FY)€1.55B
Virbac SA Business Overview & Revenue Model
Company Description
Founded in 1968 and based in Carros, France, Virbac S.A. is a prominent developer and distributor of a wide array of animal health products and services. The company's global operations extend across France, Europe, Latin America, North America, A...
How the Company Makes Money
Virbac makes money primarily by selling animal health products to veterinary professionals and animal health distributors. Its core revenue streams generally come from (1) prescription and non-prescription veterinary pharmaceuticals (therapeutics ...
Virbac SA Financial Statement Overview
Summary
Income Statement
78
Positive
Balance Sheet
82
Very Positive
Cash Flow
63
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.49B | 1.46B | 1.40B | 1.25B | 1.22B | 1.06B |
| Gross Profit | 301.09M | 517.94M | 937.60M | 809.60M | 427.27M | 378.38M |
| EBITDA | 282.31M | 277.99M | 276.26M | 230.65M | 215.55M | 199.46M |
| Net Income | 155.85M | 150.89M | 145.29M | 121.30M | 121.97M | 113.16M |
Balance Sheet | ||||||
| Total Assets | 2.08B | 1.91B | 1.85B | 1.46B | 1.36B | 1.22B |
| Cash, Cash Equivalents and Short-Term Investments | 171.05M | 122.50M | 149.63M | 175.91M | 177.38M | 172.79M |
| Total Debt | 359.51M | 288.83M | 307.01M | 120.11M | 96.86M | 95.37M |
| Total Liabilities | 863.65M | 789.18M | 805.12M | 545.81M | 521.17M | 498.84M |
| Stockholders Equity | 1.22B | 1.13B | 1.04B | 900.30M | 839.33M | 724.93M |
Cash Flow | ||||||
| Free Cash Flow | 126.66M | 103.41M | 134.97M | 77.60M | 45.41M | 79.13M |
| Operating Cash Flow | 220.85M | 195.65M | 204.22M | 118.64M | 98.98M | 126.29M |
| Investing Cash Flow | -207.10M | -199.55M | -428.69M | -121.87M | -54.83M | -51.21M |
| Financing Cash Flow | 21.81M | -5.53M | 138.59M | -2.56M | -34.76M | -91.69M |
Virbac SA Technical Analysis
Positive
323.00
Price Trends
321.99
Positive
327.87
Positive
341.60
Positive
Market Momentum
8.78
Negative
67.54
Neutral
74.77
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:VIRP, the sentiment is Positive. The current price of 323 is below the 20-day moving average (MA) of 332.22, above the 50-day MA of 321.99, and below the 200-day MA of 341.60, indicating a bullish trend. The MACD of 8.78 indicates Negative momentum. The RSI at 67.54 is Neutral, neither overbought nor oversold. The STOCH value of 74.77 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for FR:VIRP.
Virbac SA Peers Comparison
UnderperformOutperform
Sector (55)
FR:VIRP
Virbac SA
347.00
-5.94
-1.68%
FR:ERF
Eurofins Scientific
87.72
27.30
45.17%
FR:VETO
VETOQUINOL
85.00
11.41
15.50%
Virbac SA Corporate Events
Virbac Publishes Interim Financial Report for First Half of 2026
Sep 17, 2026
Virbac SA has released its interim financial report for the period ended June 30, 2026, making it publicly available and filing it with the French financial markets regulator, the Autorité des marchés financiers. The report can be access...
Virbac lifts margins and confirms 2026 targets on strong animal health growth
Sep 17, 2026
Virbac posted strong first‑half 2026 results, with revenue up 7.4% organically to €768 million and an adjusted EBIT margin of 18.8%, driven by robust growth in both companion animals and food‑producing animals. Net profit rose 5....
Virbac Updates Share Capital and Voting Rights Structure as of August 2026
Sep 7, 2026
Virbac SA reported that its share capital consists of 8,390,660 shares as of August 31, 2026, all listed on Euronext Paris. The disclosure also confirms a gross total of 12,705,412 voting rights and a net total of 12,696,376 voting rights after ex...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.